STOCK TITAN

Immunocore Holdings plc American Depositary Shares - IMCR STOCK NEWS

Welcome to our dedicated news page for Immunocore Holdings plc American Depositary Shares (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings plc American Depositary Shares.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunocore Holdings plc American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunocore Holdings plc American Depositary Shares's position in the market.

Rhea-AI Summary
Immunocore Holdings plc (Nasdaq: IMCR) announces strategic priorities and pipeline expansion, including KIMMTRAK global commercial access, two registrational trials, multiple clinical readouts, and new autoimmune disease candidates. Preliminary unaudited cash and cash equivalents are approximately $443 million USD as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
-
Rhea-AI Summary
Immunocore Holdings plc (Nasdaq: IMCR) to present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences
-
Rhea-AI Summary
Immunocore reported KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, and a cash and cash equivalents increase to £364 million ($445 million) as of September 30, 2023. The company is progressing with Phase 3 clinical trials, with long-term survival for KIMMTRAK in metastatic uveal melanoma demonstrated, and expects data in multiple tumors in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
Rhea-AI Summary
Immunocore Holdings plc will present data for KIMMTRAK in metastatic uveal melanoma and cutaneous melanoma at two scientific conferences. The company will present seven posters showcasing the results of various trials and studies related to tebentafusp, their novel TCR bispecific immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary
Immunocore Holdings Plc announced that management will present at several investor conferences in November. The conferences include TD Cowen Fall Oncology Innovation Summit, Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and 3rd Annual BTIG Ophthalmology Day. The presentations will be webcast live and can be accessed on Immunocore's website. A replay of the presentations will also be available for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
conferences
-
Rhea-AI Summary
Immunocore announces long-term survival benefit in metastatic uveal melanoma patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Immunocore announces upcoming presentation and posters at ESMO 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
conferences
-
Rhea-AI Summary
Immunocore to present at upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
conferences
-
Rhea-AI Summary
Immunocore to present at upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Immunocore Holdings plc (IMCR) reports KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023 and new launches in Italy, Austria, Finland, and Israel with additional European launches expected by year-end. Cash and cash equivalents increased to £342 million ($435 million) as of June 30, 2023. The company announced a new Phase 3 trial for IMC-F106C (PRAME-A02) in first-line cutaneous melanoma (PRISM-MEL301), expecting the first patient randomized by 1Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
Immunocore Holdings plc American Depositary Shares

Nasdaq:IMCR

IMCR Rankings

IMCR Stock Data

2.91B
32.22M
4.45%
82.24%
9.26%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
OXFORDSHIRE

About IMCR

immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.